Molecular Pharmaceutics
[ASAP] Liposomal Amphotericin B Formulation Displaying Lipid-Modified Chitin-Binding Domains with Enhanced Antifungal Activity
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00388
Molecular Pharmaceutics
[ASAP] A Positron Emission Tomography Tracer Targeting the S2 Subunit of SARS-CoV‑2 in Extrapulmonary Infections
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00584
Molecular Pharmaceutics
[ASAP] Placental Nanoparticle Uptake-On-a-Chip: The Impact of Trophoblast Syncytialization and Shear Stress
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00216
Molecular Pharmaceutics
[ASAP] Development of an In Vitro Drug Release Method to Enable In Vitro–In Vivo Correlation of Potassium Chloride Extended-Release Tablets
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00568
Molecular Pharmaceutics
[ASAP] Microcrystals of Ketal-Linked Paliperidone Prodrugs for Long-Acting Antipsychotics
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00348
Molecular Pharmaceutics
[ASAP] Implications of Coexistent Halogen and Hydrogen Bonds in Amorphous Solid Dispersions on Drug Solubility, Miscibility, and Mobility
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00434
Molecular Pharmaceutics
[ASAP] A Colon-Targeted Prodrug of Riluzole Improves Therapeutic Effectiveness and Safety upon Drug Repositioning of Riluzole to an Anti-Colitic Drug
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00255
Molecular Pharmaceutics
[ASAP] Macromolecular Dexamethasone Prodrug Ameliorates Neuroinflammation and Prevents Bone Loss Associated with Traumatic Brain Injury
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00482
Molecular Pharmaceutics
[ASAP] Host–Guest Complexation by β‑Cyclodextrin Enhances the Solubility of an Esterified Protein
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00368
Molecular Pharmaceutics
[ASAP] New Development in Understanding Drug–Polymer Interactions in Pharmaceutical Amorphous Solid Dispersions from Solid-State Nuclear Magnetic Resonance
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00479